Gni Ltd (GNIXF) 1.8900 $GNIXF
Kidney Fibrosis - Pipeline Review 2015
M2 - Wed Jan 06, 4:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/gj84k6/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - AbbVie Inc. - Angion Biomedica Corp. - Bio-inRen - BioLineRx, Ltd. - BiOrion Technologies B.V. - Cellmid Limited - Evotec AG - Galectin Therapeutics, Inc. - GenKyoTex S.A. - GNI Group Ltd. - Intercept Pharmaceuticals, Inc. - Isarna Therapeutics GmbH - Lpath, Inc. - MorphoSys AG - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. - SciFluor Life Sciences, LLC For more information visit http://www.researchandmarkets.com/research/gj...y_fibrosis
RPTP: 5.89 (-0.03), GALT: 1.64 (+0.07), ICPT: 173.03 (+6.13), RGLS: 3.57 (unch), ABBV: 66.23 (+1.51), LPTN: 1.95 (-0.05)
World Liver Cirrhosis Therapeutics Pipeline Review, H2 2015 - 13 Companies & 24 Drug Profiles
M2 - Fri Dec 11, 6:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/f583cg/liver_cirrhosis) has announced the addition of the "Liver Cirrhosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cirrhosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alfa Wassermann S.p.A - Conatus Pharmaceuticals Inc. - Digna Biotech, S.L. - Galectin Therapeutics, Inc. - Gilead Sciences, Inc. - GNI Group Ltd. - Human Stem Cells Institute - Nimbus Therapeutics, LLC - PharmaIN Corporation - Pharmicell Co., Ltd. - S-Evans Biosciences, Inc. - Stelic Institute & Co. - Stempeutics Research Private Limited Drug Profiles - (sofosbuvir velpatasvir) - Cell Therapy for Liver Cirrhosis - DB-027 - DB-036 - emricasan - F-351 - Gemacell - GR-MD-01 - GR-MD-02 - GXHPC-1 - Livercellgram - Monoclonal Antibodies to Antagonize TGF-Beta Receptor Type-1 for HCV associated Liver Cirrhosis - ND-654 - Px-104 - rifaximin - simtuzumab - Stem Cell Therapy for Liver Cirrhosis - Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders - Stem Cell Therapy for Rheumatoid Arthritis and Liver Cirrhosis - Stempeucel - STNM-04 - thrombopoietin - Undisclosed Peptide for Liver Cirrhosis For more information visit http://www.researchandmarkets.com/research/f5..._cirrhosis
GILD: 79.47 (-1.77), CNAT: 2.26 (-0.03), GALT: 1.64 (+0.07)
Liver Fibrosis - Pipeline Review, H1 2015 - Featuring 23 Therapeutics Companies
M2 - Thu Jun 11, 10:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7lgbpl/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Liver fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advinus Therapeutics Ltd. - Angion Biomedica Corp. - BerGenBio AS - BiOrion Technologies B.V. - Celgene Corporation - Digna Biotech, S.L. - FibroGen, Inc. - Galectin Therapeutics, Inc. - Genfit SA - GenKyoTex S.A. - Gilead Sciences, Inc. - GNI Group Ltd. - La Jolla Pharmaceutical Company - LG Life Sciences, Ltd. - Nitto Denko Corporation - Pharmaxis Limited - Promedior, Inc. - Promethera Biosciences S.A. - ProMetic Life Sciences Inc. - RXi Pharmaceuticals Corporation - TCM Biotech International Corp - Vascular Biogenics Ltd. - Virobay Inc. For more information visit http://www.researchandmarkets.com/research/7l...r_fibrosis
GILD: 79.47 (-1.77), GALT: 1.64 (+0.07), FGEN: 19.13 (+0.20), VBAY: (), VBLT: 4.02 (unch), CELGZ: 1.16 (-0.01)
Liver Cirrhosis Pipeline Review, H1 2015 - 12 Key Comapnies
M2 - Thu Jun 11, 9:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2ctvbp/liver_cirrhosis) has announced the addition of the "Liver Cirrhosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cirrhosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alfa Wassermann S.p.A - Conatus Pharmaceuticals Inc. - Digna Biotech, S.L. - Galectin Therapeutics, Inc. - Gilead Sciences, Inc. - GNI Group Ltd. - Pacific Therapeutics Ltd. - PharmaIN Corporation - Pharmicell Co., Ltd. - S-Evans Biosciences, Inc. - Stelic Institute & Co. - Stempeutics Research Private Limited For more information visit http://www.researchandmarkets.com/research/2c..._cirrhosis
GILD: 79.47 (-1.77), CNAT: 2.26 (-0.03), GALT: 1.64 (+0.07)
Kidney Fibrosis - Pipeline Review, H1 2015 - 13 Companies & 19 Drug Profiles
M2 - Wed Jun 10, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qhppdp/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Angion Biomedica Corp. - Bio-inRen - BioLineRx, Ltd. - BiOrion Technologies B.V. - Galectin Therapeutics, Inc. - GNI Group Ltd. - Lpath, Inc. - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. - RestorGenex Corporation - Tobira Therapeutics, Inc. Drug Profiles - ANG-3298 - ANG-4011 - BOT-191 - BRN-1889 - cenicriviroc mesylate - CGEN-856 - CT-140 - cysteamine DR - F-351 - Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - GR-MD-02 - ICG-001 - LJ-1888 - Lpathomab - P-007 - P-529 - PBI-4050 - RG-012 - Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis For more information visit http://www.researchandmarkets.com/research/qh...y_fibrosis
RPTP: 5.89 (-0.03), GALT: 1.64 (+0.07), RGLS: 3.57 (unch), ABBV: 66.23 (+1.51), TBRA: 4.31 (+0.04), LPTN: 1.95 (-0.05)
Global Diabetic Nephropathy Pipeline Review, H1 2015
M2 - Tue Jun 02, 7:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frxw7k/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Bristol-Myers Squibb Company - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dimerix Bioscience Pty Ltd - Dong Wha Pharma Co., Ltd. - Eli Lilly and Company - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gentium S.p.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Glucox Biotech AB - GNI Group Ltd. - IMMD Inc. - Intercept Pharmaceuticals, Inc. - InterMune, Inc. - Inventiva SAS - Islet Sciences, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Mallinckrodt plc - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG For more information visit http://www.researchandmarkets.com/research/frxw7k/diabetic
NRX: 0.14 (+0.01), GALT: 1.64 (+0.07), LLY: 82.89 (-0.04), GSK: 45.07 (-0.11), BMY: 74.81 (+0.15), CTIC: 0.34 (+0.01), CNCE: 11.49 (-0.28), JNJ: 125.23 (+0.77), GILD: 79.47 (-1.77), AZN: 34.14 (-0.15), CCXI: 4.70 (+0.01), ICPT: 173.03 (+6.13), ABBV: 66.23 (+1.51)
Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com
PRWeb - Tue May 05, 5:21AM CDT
The report "Liver Fibrosis - Pipeline Review, H2 2014" provides comparative analysis on the therapeutic development for Liver Fibrosis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/liver-fibros...eport.html .
GILD: 79.47 (-1.77), PFE: 36.89 (+0.22), GALT: 1.64 (+0.07), FGEN: 19.13 (+0.20), CELGZ: 1.16 (-0.01)
GNI Group Ltd. - Product Pipeline Review - 2014
M2 - Fri Apr 17, 3:37AM CDT
Product Pipeline Review - 2014
Liver Fibrosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/wmnbdp/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Fibrosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Genzyme - Gilead Sciences - Bioneer - FibroGen - Silence Therapeutics - Celgene - Nitto Denko - Genfit - Pharmaxis - La Jolla Pharmaceutical - ProMetic Life Sciences - LG Life Sciences - Digna Biotech - Advinus Therapeutics - Promedior - GenKyoTex - Angion Biomedica - Virobay - Intercept Pharmaceuticals - Tobira Therapeutics - GNI Group - Promethera Biosciences - BiOrion Technologies - ACROVIS biostructures - RXi Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/wm...r_fibrosis
GILD: 79.47 (-1.77), ICPT: 173.03 (+6.13), TBRA: 4.31 (+0.04), CELGZ: 1.16 (-0.01)
Kidney Fibrosis - Pipeline Review 2015
M2 - Wed Jan 06, 4:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/gj84k6/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - AbbVie Inc. - Angion Biomedica Corp. - Bio-inRen - BioLineRx, Ltd. - BiOrion Technologies B.V. - Cellmid Limited - Evotec AG - Galectin Therapeutics, Inc. - GenKyoTex S.A. - GNI Group Ltd. - Intercept Pharmaceuticals, Inc. - Isarna Therapeutics GmbH - Lpath, Inc. - MorphoSys AG - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. - SciFluor Life Sciences, LLC For more information visit http://www.researchandmarkets.com/research/gj...y_fibrosis
RPTP: 5.89 (-0.03), GALT: 1.64 (+0.07), ICPT: 173.03 (+6.13), RGLS: 3.57 (unch), ABBV: 66.23 (+1.51), LPTN: 1.95 (-0.05)
World Liver Cirrhosis Therapeutics Pipeline Review, H2 2015 - 13 Companies & 24 Drug Profiles
M2 - Fri Dec 11, 6:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/f583cg/liver_cirrhosis) has announced the addition of the "Liver Cirrhosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cirrhosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alfa Wassermann S.p.A - Conatus Pharmaceuticals Inc. - Digna Biotech, S.L. - Galectin Therapeutics, Inc. - Gilead Sciences, Inc. - GNI Group Ltd. - Human Stem Cells Institute - Nimbus Therapeutics, LLC - PharmaIN Corporation - Pharmicell Co., Ltd. - S-Evans Biosciences, Inc. - Stelic Institute & Co. - Stempeutics Research Private Limited Drug Profiles - (sofosbuvir velpatasvir) - Cell Therapy for Liver Cirrhosis - DB-027 - DB-036 - emricasan - F-351 - Gemacell - GR-MD-01 - GR-MD-02 - GXHPC-1 - Livercellgram - Monoclonal Antibodies to Antagonize TGF-Beta Receptor Type-1 for HCV associated Liver Cirrhosis - ND-654 - Px-104 - rifaximin - simtuzumab - Stem Cell Therapy for Liver Cirrhosis - Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders - Stem Cell Therapy for Rheumatoid Arthritis and Liver Cirrhosis - Stempeucel - STNM-04 - thrombopoietin - Undisclosed Peptide for Liver Cirrhosis For more information visit http://www.researchandmarkets.com/research/f5..._cirrhosis
GILD: 79.47 (-1.77), CNAT: 2.26 (-0.03), GALT: 1.64 (+0.07)
Liver Fibrosis - Pipeline Review, H1 2015 - Featuring 23 Therapeutics Companies
M2 - Thu Jun 11, 10:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7lgbpl/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Liver fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advinus Therapeutics Ltd. - Angion Biomedica Corp. - BerGenBio AS - BiOrion Technologies B.V. - Celgene Corporation - Digna Biotech, S.L. - FibroGen, Inc. - Galectin Therapeutics, Inc. - Genfit SA - GenKyoTex S.A. - Gilead Sciences, Inc. - GNI Group Ltd. - La Jolla Pharmaceutical Company - LG Life Sciences, Ltd. - Nitto Denko Corporation - Pharmaxis Limited - Promedior, Inc. - Promethera Biosciences S.A. - ProMetic Life Sciences Inc. - RXi Pharmaceuticals Corporation - TCM Biotech International Corp - Vascular Biogenics Ltd. - Virobay Inc. For more information visit http://www.researchandmarkets.com/research/7l...r_fibrosis
GILD: 79.47 (-1.77), GALT: 1.64 (+0.07), FGEN: 19.13 (+0.20), VBAY: (), VBLT: 4.02 (unch), CELGZ: 1.16 (-0.01)
Liver Cirrhosis Pipeline Review, H1 2015 - 12 Key Comapnies
M2 - Thu Jun 11, 9:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2ctvbp/liver_cirrhosis) has announced the addition of the "Liver Cirrhosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cirrhosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alfa Wassermann S.p.A - Conatus Pharmaceuticals Inc. - Digna Biotech, S.L. - Galectin Therapeutics, Inc. - Gilead Sciences, Inc. - GNI Group Ltd. - Pacific Therapeutics Ltd. - PharmaIN Corporation - Pharmicell Co., Ltd. - S-Evans Biosciences, Inc. - Stelic Institute & Co. - Stempeutics Research Private Limited For more information visit http://www.researchandmarkets.com/research/2c..._cirrhosis
GILD: 79.47 (-1.77), CNAT: 2.26 (-0.03), GALT: 1.64 (+0.07)
Kidney Fibrosis - Pipeline Review, H1 2015 - 13 Companies & 19 Drug Profiles
M2 - Wed Jun 10, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qhppdp/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Angion Biomedica Corp. - Bio-inRen - BioLineRx, Ltd. - BiOrion Technologies B.V. - Galectin Therapeutics, Inc. - GNI Group Ltd. - Lpath, Inc. - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. - RestorGenex Corporation - Tobira Therapeutics, Inc. Drug Profiles - ANG-3298 - ANG-4011 - BOT-191 - BRN-1889 - cenicriviroc mesylate - CGEN-856 - CT-140 - cysteamine DR - F-351 - Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - GR-MD-02 - ICG-001 - LJ-1888 - Lpathomab - P-007 - P-529 - PBI-4050 - RG-012 - Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis For more information visit http://www.researchandmarkets.com/research/qh...y_fibrosis
RPTP: 5.89 (-0.03), GALT: 1.64 (+0.07), RGLS: 3.57 (unch), ABBV: 66.23 (+1.51), TBRA: 4.31 (+0.04), LPTN: 1.95 (-0.05)
Global Diabetic Nephropathy Pipeline Review, H1 2015
M2 - Tue Jun 02, 7:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frxw7k/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Bristol-Myers Squibb Company - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dimerix Bioscience Pty Ltd - Dong Wha Pharma Co., Ltd. - Eli Lilly and Company - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gentium S.p.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Glucox Biotech AB - GNI Group Ltd. - IMMD Inc. - Intercept Pharmaceuticals, Inc. - InterMune, Inc. - Inventiva SAS - Islet Sciences, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Mallinckrodt plc - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG For more information visit http://www.researchandmarkets.com/research/frxw7k/diabetic
NRX: 0.14 (+0.01), GALT: 1.64 (+0.07), LLY: 82.89 (-0.04), GSK: 45.07 (-0.11), BMY: 74.81 (+0.15), CTIC: 0.34 (+0.01), CNCE: 11.49 (-0.28), JNJ: 125.23 (+0.77), GILD: 79.47 (-1.77), AZN: 34.14 (-0.15), CCXI: 4.70 (+0.01), ICPT: 173.03 (+6.13), ABBV: 66.23 (+1.51)
Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com
PRWeb - Tue May 05, 5:21AM CDT
The report "Liver Fibrosis - Pipeline Review, H2 2014" provides comparative analysis on the therapeutic development for Liver Fibrosis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/liver-fibros...eport.html .
GILD: 79.47 (-1.77), PFE: 36.89 (+0.22), GALT: 1.64 (+0.07), FGEN: 19.13 (+0.20), CELGZ: 1.16 (-0.01)
GNI Group Ltd. - Product Pipeline Review - 2014
M2 - Fri Apr 17, 3:37AM CDT
Product Pipeline Review - 2014
Liver Fibrosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/wmnbdp/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Fibrosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Genzyme - Gilead Sciences - Bioneer - FibroGen - Silence Therapeutics - Celgene - Nitto Denko - Genfit - Pharmaxis - La Jolla Pharmaceutical - ProMetic Life Sciences - LG Life Sciences - Digna Biotech - Advinus Therapeutics - Promedior - GenKyoTex - Angion Biomedica - Virobay - Intercept Pharmaceuticals - Tobira Therapeutics - GNI Group - Promethera Biosciences - BiOrion Technologies - ACROVIS biostructures - RXi Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/wm...r_fibrosis
GILD: 79.47 (-1.77), ICPT: 173.03 (+6.13), TBRA: 4.31 (+0.04), CELGZ: 1.16 (-0.01)
